$GOVX News
Last published 1d ago
- 1d agoGOVXTrading halt: GeoVax Labs, Inc. Cmn Stk (GOVX), News pendingNasdaq Trading HaltsHalted 2026-11-10 19:50:00.000 ET, resumption quote none, resumption trade none.
- 5mo agoGOVX"Ebola, Marburg, Hantavirus, Mpox and Beyond" GeoVax CEO, David Dodd - GEOVAX LABS INCEarnings Call TranscriptsGood morning, everyone. My name is John Hirdink, and welcome to our Tribe Public CEO presentation titled Ebola, Marburg, Antivirus, Impox, and Beyond, Building a Resilient Infectious Disease Portfolio Preparedness Strate
- 1y agoGOVXEmerging Growth Conference - GEOVAX LABS INCEarnings Call TranscriptsWelcome back. We have an update from Geovax Labs, trades on the NASDAQ under GOVX. It's a clinical stage biotech company developing novel vaccines for many of the world's most threatening infectious diseases and therapie
- 1y agoADVMCLNNCUAUFDERM+27Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live streamGlobeNewswireMIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth
- 1y agoGOVXGeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoGOVXGOVXWGeoVax Receives Notice of Allowance For Cancer Vaccine PatentGlobeNewswireAdds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against
- 1y agoGOVXGOVXWGeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity ConferenceGlobeNewswireATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO,
- 1y agoGOVXGOVXWGeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaGlobeNewswireGEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and
- 1y agoGOVXGeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoGOVXGOVXWGeoVax Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireProgress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2
- 2y agoGOVXGOVXWGeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024GlobeNewswireGeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and
- 2y agoGOVXGOVXWGeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceGlobeNewswireATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman &
- 2y agoGOVXGOVXWGeoVax to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its
- 2y agoGOVXGOVXWGeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-MarketGlobeNewswireATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced
- 2y agoGOVXGOVXWRegistration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab's CEOGlobeNewswireCompany to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc.
- 2y agoGOVXGOVXWGeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-MarketGlobeNewswireATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced
- 2y agoGOVXGOVXWGeoVax to Present at the Emerging Growth Conference on August 21, 2024GlobeNewswireCompany to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc.
- 2y agoGOVXGeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoGOVXGOVXWGeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory BoardGlobeNewswireStrategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
- 2y agoGOVXGOVXWGeoVax Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireAwarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents
- 2y agoGOVXGOVXWUpdate: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee ReviewGlobeNewswireCompany plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a
- 2y agoGOVXGOVXWGeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee ReviewGlobeNewswireCompany plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a
- 2y agoGOVXGOVXWGeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024GlobeNewswireGeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against
- 2y agoAZNGOVXGSKMRK+1Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market GrowthGlobeNewswirePALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute's (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. A
- 2y agoGOVXGeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoGOVXGOVXWGeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineGlobeNewswirePresentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies
- 2y agoGOVXGOVXWGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressGlobeNewswireATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
- 2y agoGOVXGOVXWGeoVax to Present at the 36th Annual Roth ConferenceGlobeNewswireATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced
- 2y agoGOVXGOVXWGeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing SystemGlobeNewswireManufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a
- 2y agoGOVXGeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoGOVXGOVXWGeoVax Reports 2023 Year-End Financial Results and Provides Business UpdateGlobeNewswireProgress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study of Gedeptin®, targeting advanced head and neck
- 2y agoGOVXGOVXWGeoVax to Present at the 2024 BIO CEO & Investor ConferenceGlobeNewswireATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced
- 2y agoGOVXGOVXWGeoVax Announces Multiple Patent Issuances and AllowancesGlobeNewswireIntellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a
- 2y agoGOVXGOVXWGeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine BoosterGlobeNewswireResults Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company
- 2y agoGOVXGOVXWGeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementGlobeNewswireATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious
- 2y agoGOVXGOVXWGeoVax Appoints Dr. Marc Pipas as Executive Medical Director, OncologyGlobeNewswireStrengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
- 2y agoGOVXGOVXWGeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer PatientsGlobeNewswireTherapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax
- 2y agoGOVXGOVXWGeoVax Announces Issuance of Malaria Vaccine PatentGlobeNewswirePatent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
- 2y agoGOVXGOVXWGeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024GlobeNewswireATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
- 2y agoGOVXGOVXWGeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxGlobeNewswireATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
- 2y agoGOVXGOVXWGeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine CongressGlobeNewswire80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
- 2y agoGOVXGOVXWGeoVax to Participate in Upcoming December Investor EventsGlobeNewswireATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
- 2y agoGOVXGOVXWGeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine CongressGlobeNewswirePresentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA, GA, Nov. 28, 2023
- 2y agoGOVXGOVXWProgress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023GlobeNewswireSingle-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
- 3y agoGOVXGOVXWGeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireSignificant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck Cancer Conference
- 3y agoGOVXGOVXWGeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023GlobeNewswireGeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and
- 3y agoGOVXGOVXWGeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 VaccineGlobeNewswireDesigned to Protect Immunocompromised Patients Against Severe COVID-19 ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
- 3y agoGOVXGOVXWGeoVax to Participate in Upcoming November Investor and Industry EventsGlobeNewswireATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
- 3y agoGOVXGOVXWGeoVax Update: Clinical and Operational Progress Toward Transformative OpportunitiesGlobeNewswireATLANTA, GA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
- 3y agoGOVXGOVXWGeoVax Receives Notice of Allowance for Marburg Vaccine PatentGlobeNewswireATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today